Provided here is the agenda for the Gilead and Galapagos organised and funded symposium taking place during the EULAR 2020 E-Congress which will look at the great progress that has been made in the management of rheumatoid arthritis and the improvements that are continuously evolving. Background on the leading experts who will be presenting is also available and following the event you will be able to access highlights from the symposium as well as hear views from your peers.

In Darwin’s footsteps Adaptation through innovation in RA

Thursday 4th June 2020. 08:15–09:30 (CEST) and thereafter available on demand

  • Professor
    Georg Schett

  • Professor
    Ronald van Vollenhoven

  • Professor
    Kunihiro Yamaoka

  • Professor
    Maya Buch

Professor
Georg Schett

Professor of Internal Medicine and Head of Department of Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, Germany

Georg Schett is Professor of Internal Medicine and, since 2006, Head of the Department of Medicine 3 – Rheumatology and Immunology, at the Friedrich-Alexander University Erlangen-Nürnberg in Germany.

Professor Schett graduated from the University of Innsbruck, Austria in 1994. After graduating from medical school, he worked as a scientist at the Institute of BioMedical Aging Research of the Austrian Academy of Science in Innsbruck. In 1996, Professor Schett joined the Department of Medicine at the University of Vienna, where he completed his postgraduate training in internal medicine and subsequently in rheumatology. In 2003, he was promoted to Professor of Internal Medicine. Before taking up his position as Chair of the Department of Medicine 3, Professor Schett worked for 1 year as a scientist in the United States.

Professor Schett’s scientific work focuses on creating a better understanding of the molecular basis of immune-inflammatory diseases with rapid translation into clinical practice. Initially, he investigated the immunology of atherosclerosis and focused on antibody-mediated endothelial cell damage. In 2007, his research work led to the understanding of the phenomenon of lupus erythematosus cells. He was awarded the renowned START award in 2002 and founded a research group for arthritis in Vienna. Professor Schett is a European Research Council (ERC) award winner and speaker of several German Research Foundation (DFG) and Federal Ministry of Education and Research (BMBF) funded joint projects. His work has been awarded numerous prizes, including the Carol Nachman Prize, and has been published in over 650 scientific articles.

Professor
Ronald van Vollenhoven

Chair of Rheumatology, Department of Rheumatology and Clinical Immunology Amsterdam University Medical Centers, Amsterdam, The Netherlands

Ronald F van Vollenhoven is Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam University Medical Centers (UMC) and Director of the Amsterdam Rheumatology and Immunology Center (ARC) in Amsterdam, the Netherlands.

Previously, in 2010, he was appointed Professor and Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at the Karolinska Institute. In January 2016, he was appointed as Professor of Rheumatology at the University of Amsterdam and the VU University, and Chair of Rheumatology at the Department of Rheumatology and Clinical Immunology of the Amsterdam UMC.

Professor van Vollenhoven’s research interests focus on the development and systematic evaluation of novel treatments for the rheumatic diseases. With his co-workers, he established the Stockholm registry for biological therapies (the STURE database) and has been principal investigator in, or contributed to, many clinical trials in rheumatoid arthritis and systemic lupus erythematosus (SLE). He has published over 400 original papers (H-index: 75), book chapters and reviews, and is editor or associate editor of several prominent journals. Professor van Vollenhoven is an honorary member of several rheumatological societies, and in 2019 he was awarded the Dutch Society of Rheumatology’s highest award, the Jan van Breemen medal. He is a member of the EULAR Executive Committee, past-Chair of the Swedish Society of Rheumatology Professors’ Council, co-founder of the IRBIS registry for biologics in SLE, the CERERRA registries collaboration and the NORD-STAR collaboration, and the initiator of the Treat-to-Target-in-SLE and DORIS initiatives.

Professor
Kunihiro Yamaoka

Professor and Chairman, Department of Rheumatology and Infectious Diseases Kitasato University, Tokyo, Japan

Kunihiro Yamaoka is Professor and Chairman of the Department of Rheumatology and Infectious Diseases at Kitasato University in Tokyo, Japan. His major interest is in translational research, focusing on innate immunity and cytokine signalling in rheumatic diseases. Professor Yamaoka spent some time at the National Institutes of Health (NIH) analysing the JAK-STAT pathway in innate immune cells, and thereafter, focused on the mechanism of action of JAK inhibitors in rheumatoid arthritis (RA) in mice and humans. Currently, he is investigating the possibility of JAK inhibitors in non-RA diseases and working on novel pathways that relate to disease activity of RA.

Professor
Maya Buch

Professor of Rheumatology and Director of Experimental Medicine Centre for Musculoskeletal Research, University of Manchester, United Kingdom

Maya Buch recently took up a new position as Professor of Rheumatology and Director of Experimental Medicine in the Centre for Musculoskeletal Research at the University of Manchester having moved from the University of Leeds, where she retains a visiting professor position. She has established a clinical translational and experimental research programme in rheumatoid arthritis and targeted therapies, and cardiovascular pathology in immune-mediated inflammatory diseases. Professor Buch directs a broad research portfolio spanning clinical trials and complex observational investigation to experimental studies. She has additional clinical and research interests in the rare disease scleroderma.

GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies. GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos N.V. © 2020 Galapagos NV. © 2020 Gilead Sciences, Inc. All rights reserved.

IHQ-INF-2020-04-0012

Date of preparation: July 2020